Cagrilintide Clinical Trials: What Monotherapy and CagriSema Studies Actually Test
Direct answer: cagrilintide clinical trials do not all test the same intervention. Some evaluate cagrilintide alone, while others evaluate cagrilintide coadministered with semaglutide as CagriSema. Their comparators, populations, durations, endpoints, and trial phases differ, so a combination result cannot be assigned automatically to cagrilintide monotherapy or to a premixed research blend.
Start by naming the intervention exactly
Cagrilintide is a long-acting amylin analogue. CagriSema is a clinical development program in which cagrilintide and semaglutide are coadministered. A study arm labeled CagriSema therefore tests two active molecules and a particular protocol. It is not evidence that every material containing both names has the same composition, exposure, stability, or outcome.
The cagrilintide research-record guide explains how receptor terminology and source matching should be preserved. The CagriSema evidence guide focuses specifically on why coadministration evidence does not validate an arbitrary premixed blend.
What have major trials tested?
| Trial or publication | Intervention and comparator | Main evidence boundary |
|---|---|---|
| Phase 2 dose-finding, NCT03856047 | Cagrilintide monotherapy across dose groups, versus placebo and liraglutide | Monotherapy in adults with overweight or obesity without diabetes |
| Phase 1b combination study | Cagrilintide or placebo added to semaglutide | Early safety, tolerability, PK, and PD of concomitant administration |
| Phase 2, NCT04982575 | CagriSema versus semaglutide versus cagrilintide | Adults with type 2 diabetes; 32-week endpoints |
| REDEFINE 1 Phase 3 | CagriSema, semaglutide, cagrilintide, and placebo arms | Adults with overweight/obesity; defined 68-week protocol |
| REDEFINE 3, NCT05669755 | CagriSema versus placebo | Ongoing cardiovascular outcomes program; results not established by registration alone |
The cagrilintide monotherapy Phase 2 trial randomized 706 participants across cagrilintide dose groups and included liraglutide and placebo comparators. Its primary question concerned dose response over 26 weeks in a defined population (Lau et al., PubMed 34798060). That design should not be summarized as a CagriSema trial.
A later Phase 2 trial randomized 92 participants with type 2 diabetes to CagriSema, semaglutide, or cagrilintide for 32 weeks. Its HbA1c and body-weight results belong to that population, duration, escalation scheme, and set of comparators (Frias et al., PubMed 37364590).
What changed in Phase 3?
REDEFINE 1 expanded the evidence base to 3,417 randomized participants with overweight or obesity and compared CagriSema with placebo while retaining separate semaglutide and cagrilintide arms. The published report describes a 68-week protocol and specific efficacy and safety endpoints (PubMed 40544433). These results strengthen evidence for the tested CagriSema program; they do not erase the difference between the combination and its components.
REDEFINE 3 asks a different question: cardiovascular safety and efficacy in participants with established cardiovascular disease. Its ClinicalTrials.gov record lists 7,101 participants, an active-not-recruiting status, and an estimated primary completion in 2027 (ClinicalTrials.gov NCT05669755). Until results are available, registration shows the design and status—not the outcome.
How should trial results be compared?
Keep at least six fields beside every number: intervention, comparator, population, duration, endpoint, and estimand. Also record whether the value is observed, model-estimated, primary, secondary, exploratory, or safety-related. A percentage change in one trial should not be compared directly with another if the population, follow-up, handling of missing data, or treatment policy differs.
The cagrilintide modification-mapping guide adds the analytical layer: clinical results for a defined reference intervention do not verify the sequence, lipidation site, disulfide, content, or stability of an unrelated sample.
For catalog navigation, Cagrilintide research material and Semaglutide research material remain separate product records within the GLP-1 research collection. Batch-specific analytical fields should be checked through the NEXTWAVE PEPTIDES COA library, and absence of a test should be stated directly.
The cagrilintide half-life guide traces the 159–195-hour range to a Phase 1b pharmacokinetic study and separates it from trial outcomes and batch specifications.
Research limitations
Trial registries can change, and some registered outcomes may not yet be published or peer reviewed. Sponsor-funded studies require the same method-level reading as other research. Clinical results apply to the studied product, protocol, and participants; they do not establish the identity, purity, safety, or effectiveness of research materials. This article provides no dosing or human-use guidance.
Frequently asked questions
Is every cagrilintide trial a CagriSema trial?
No. Some trials test cagrilintide alone, while CagriSema trials test cagrilintide with semaglutide.
Does a CagriSema result prove what cagrilintide alone will do?
No. Component arms can help comparison, but the combination and monotherapy remain different interventions.
Does a registered Phase 3 trial mean the product is approved?
No. Trial phase and regulatory approval are separate records.
Can clinical trial data validate a research blend?
No. A research blend needs its own identity, composition, content, stability, and lot documentation.